THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY

Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori
  • Ercole Brusamolino
    Ercole Brusamolino, M.D., Clinica Ematologica, Department of OncoHematology, Fondazione IRCCS Policlinico San Matteo, Piazzale Golgi 2, Pavia 27100, Italy, Italy | ercole.brusamolino@humanitas.it
  • Manuel Gotti
    Affiliation not present
  • Valeria Fiaccadori
    Affiliation not present

Abstract

Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/AML). With the introduction of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, this risk has substantially been reduced. In this review, different experiences are discussed to determine whether and how modifications of treatment in different cohorts of patients have reduced the overall risk of secondary MDS/AML. These data are drawn from large cohorts of patients treated over time with different therapies with an adequate follow-up.

Full Text:

PDF
HTML
Submitted: 2014-06-13 09:29:45
Published: 2012-04-06 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
720

Views:
PDF
168
HTML
1570

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185